Innovent's mazdutide meets endpoints in phase III obesity trial – BioWorld Online

Related posts:

1. ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines ESMO, the European Society for Medical Oncology, has announced today the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients....
2. What Good Is a Vaccine When There Is No Rice? The 1970s was the deadliest decade in the “entire history of Bangladesh,” said environmental historian......
3. FDA Approves JAK Inhibitor That Addresses Anemia in Myelofibrosis The FDA approved momelotinib (Ojjaara) as the first therapy specifically for intermediate- and high-risk myelofibrosis......
4. Anticoagulant medications: Newer, easier to manage medications may not always be the best choice If you are over age 75, and taking an anticoagulant, the old standard may be the gold standard, Mayo Clinic researchers and collaborators have determined....
5. Trauma-Informed Policing: Cops, COVID and TIC Trauma-Informed Policing: Cops, COVID and TIC – TIC Training Center ......